Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 6/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2317055 | 0.86 | AKR1C3 (0.50) | SMN1; SMN2POLBKDM4EAKR1C3AKR1C2 | |
| SCHEMBL10112008 | 0.86 | ALDH1A1 (0.54) | SMN1; SMN2POLBKDM4EALDH1A1HSD17B10 | |
| SCHEMBL13469239 | 0.86 | SMN1; SMN2 (0.57) | SMN1; SMN2POLBKDM4EAKR1C3AKR1C2 | |
| SCHEMBL149036 | 0.85 | KDM4E (0.55) | SMN1; SMN2POLBKDM4EALDH1A1HSD17B10 | |
| SCHEMBL8482547 | 0.84 | SMN1; SMN2 (0.56) | SMN1; SMN2POLBKDM4EAKR1C3AKR1C2 | |
| SCHEMBL8482552 | 0.84 | SMN1; SMN2 (0.60) | SMN1; SMN2POLBKDM4EAKR1C3AKR1C2 | |
| SCHEMBL11608784 | 0.83 | KDM4E (0.50) | SMN1; SMN2KDM4EAKR1C3AKR1C2ALDH1A1 | |
| SCHEMBL8338550 | 0.83 | SMN1; SMN2 (0.54) | SMN1; SMN2POLBKDM4EAKR1C3AKR1C2 | |
| SCHEMBL1399960 | 0.83 | HSD17B10 (0.63) | SMN1; SMN2POLBKDM4EAKR1C3AKR1C2 | |
| SCHEMBL18280327 | 0.83 | SMN1; SMN2 (0.54) | SMN1; SMN2POLBKDM4EAKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3924349-B1 | AMINO ACID DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | THE ROSKAMP INST (US) | 2025-06-25 | — | — | EP | disclosed |
| EP-3303415-B1 | VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF | ALCON INC (CH) | 2022-12-28 | — | — | EP | disclosed |
| US-20220081415-A1 | Amino Acid Derivatives for the Treatment of Inflammatory Diseases | THE ROSKAMP INST (US) | 2022-03-17 | — | — | US | disclosed |
| EP-3924349-A2 | AMINO ACID DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | The Roskamp Institute (US) | 2021-12-22 | — | — | EP | disclosed |
| CN-113614074-A | Amino acid derivatives for the treatment of inflammatory diseases | 罗斯坎普研究所 | 2021-11-05 | — | — | CN | disclosed |
| US-10324311-B2 | Visible-light photoinitiators and uses thereof | NOVARTIS AG (CH) | 2019-06-18 | — | — | US | disclosed |
| EP-3303415-A1 | VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF | Novartis AG (CH) | 2018-04-11 | — | — | EP | disclosed |
| US-20160357031-A1 | VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF | ALCON INC. (CH) | 2016-12-08 | — | — | US | disclosed |
| WO-2016193912-A1 | VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF | NOVARTIS AG (CH) | 2016-12-08 | — | — | WO | disclosed |
| EP-0832891-B1 | Dihydrobenzo (B) indeno (2,1-D) thiophene compounds, intermediates, processes, compositions, and methods | LILLY CO ELI (US) | 2003-07-30 | — | — | EP | disclosed |
| EP-0832890-B1 | Benzo (B) indeno (2,1-D) thiophene compounds, intermediates, processes, compositions, and methods | LILLY CO ELI (US) | 2003-07-02 | — | — | EP | disclosed |
| US-6133458-A | FOR INHIBITING BONE LOSS OR BONE RESORPTION, PARTICULARLY OSTEOPOROSIS, CARDIOVASCULAR-RELATED PATHOLOGICAL CONDITIONS INCLUDING HYPERLIPIDEMIA AND RELATED CARDIOVASCULAR PATHOLOGIES, AND ESTROGEN-DEPENDENT CANCER | ELI LILLY AND COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| US-5856341-A | INHIBITING BONE LOSS OR BONE RESORPTION, PARTICULARLY OSTEOPOROSIS, CARDIOVASCULAR-RELATED PATHOLOGICAL CONDITIONS INCLUDING HYPERLIPIDEMIA, ESTROGEN-DEPENDENT CANCER | ELI LILLY AND COMPANY (US) | 1999-01-05 | — | — | US | disclosed |
| US-5834488-A | INHIBIT BONE LOSS OR BONE RESORPTION, LOWER SERUM CHOLESTEROL LEVELS, INHIBIT ESTROGEN-DEPENDENT CANCER | ELI LILLY AND COMPANY (US) | 1998-11-10 | — | — | US | disclosed |
| EP-0832890-A1 | Benzo (B) indeno (2,1-D) thiophene compounds, intermediates, processes, compositions, and methods | ELI LILLY AND COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0832891-A1 | Dihydrobenzo (B) indeno (2,1-D) thiophene compounds, intermediates, processes, compositions, and methods | ELI LILLY AND COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10324311-B2 | Visible-light photoinitiators and uses thereof | SIRT5, IK, IGLV6-57 | SMN1; SMN2 4875/4885POLB 2831/4885KDM4E 389/4885 |
| US-20160357031-A1 | VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF | SIRT5, IK, IGLV6-57 | SMN1; SMN2 4875/4885POLB 2831/4885KDM4E 389/4885 |
| US-20220081415-A1 | Amino Acid Derivatives for the Treatment of Inflammatory Diseases | NFKBIA, NFRKB, IKBKG | SMN1; SMN2 3021/4885POLB 634/4885KDM4E 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.